Cardiology

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

Andrew Wang, MD; James Januzzi, MD; Michelle M. Kittleson, MD, PhD; and Milind Desai, MD, MBA, share a look into the future of oHCM treatment.

Michelle M. Kittleson, MD, PhD, comments on remaining unanswered questions regarding CMIs in treatment of oHCM, highlighting disease modification.

Expert cardiologists share approaches to implementing mavacamten and aficamten in the clinical treatment of oHCM.

A 20-year analysis reveals over 25% of US adults have cardiac, renal, or metabolic conditions, with disparities in age and race.

Long-term data from NODE-302 suggests self-administered etripamil nasal spray for rapid heartbeat during PSVT well-tolerated and effective.

Incidental CAC detection on ASCVD risk assessment revealed differences in prevalence by age, sex, and race and ethnicity.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Andrew Wang, MD, and Anjali Owens, MD, review the clinical trials of aficamten, a CMI used for treating patients with oHCM.

Milind Desai, MD, MBA, and Michelle M. Kittleson, MD, PhD, review the clinical trial data of mavacamten, the first FDA-approved cardiac myosin inhibitor for the treatment of oHCM.

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

The reasons many patients do not reach LDL-cholesterol thresholds.

A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.